Directorate Change

RNS Number : 9496Y

Sareum Holdings PLC

11 July 2008

 

Sareum Holdings PLC ('Sareum' or 'the Company')

Resignation of Director

Sareum Holdings plc (Sareum) (AIM: SAR), the specialist structure-based drug discovery business, announces today that Giorgio Reggiani has resigned from the board of the Company with immediate effect.

Sareum Holdings

01223 497700

Tim Mitchell, Chief Executive Officer

Grant Thornton UK LLP

020 7383 5100

Philip Secrett/ Colin Aaronson

Buchanan Communications

020 7466 5000

Tim Anderson, Mary-Jane Johnson

Notes for editors:

About Sareum Holdings plc

Sareum Holdings plc is a structure-based drug discovery business headquartered in Cambridge, UK. The Company was formed in August 2003 to discover new drugs for the treatment of cancer. Sareum's unique approach aims to halve the time it takes to discover new drug candidates.

A structure-based approach to drug discovery relies on knowledge of the three-dimensional structure of the proteins that cause disease. Once the structure is known, potential drugs are designed to 'lock-in' to the protein with the aim of reversing or arresting a disease's progression. Knowledge of the structure of the potential drugs and how they 'lock-in' to their target protein assists greatly in the development of high-quality drug candidates. Determining structure is a complex task and requires leading-edge equipment and experienced staff. Sareum's approach to structure determination utilises its proprietary protein expression platform in order to produce multiple recombinant proteins that accelerate structure determination using x-ray crystallography.

Once the structure is determined, the Company's innovative fragment screening platform is used to identify novel chemical templates designed to interact with the target protein. Sareum then uses its high-throughput medicinal chemistry platform to rapidly optimise these molecules and develop the most promising into potential drug candidates.

Sareum aims to successfully deliver drug candidates for licensing to larger pharmaceutical companies at the pre-clinical or early clinical trials stage. This is funded by provision of its specialist drug discovery capabilities to partners in the pharmaceutical and biotechnology industries.

Sareum joined the AIM market of the London Stock Exchange in October 2004 and trades under the symbol SAR. For further information, please visit www.sareum.co.uk 

 

END

 

 

BOAKGGMNVMRGRZM